This month, patent court trial proceedings are expected to get underway in the UK in Celltrion’s bid to secure a declaration that the local part of a key European patent shielding Novartis/Genentech’s Xolair (omalizumab) is invalid, or not infringed, by the Korean firm’s Omlyclo version.
What’s Next? Five Things To Look Out For In October
UK Xolair And US Abilify Maintena Patent Trials; Eleventh Generics Awards In Milan
Generics Bulletin previews the most notable and anticipated events for October 2024.
